Microbicide development

Public Health Aspects of HIV/AIDS in Low and Middle Income Countries: Epidemiology, Prevention and Care

Volumn , Issue , 2008, Pages 115-133

  McGowan, Ian ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84892022304     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-0-387-72711-0_6     Document Type: Chapter

References (44)

1. Abbas, U. L., Anderson, R. M., & Mellors, J. W. (2007). Potential impact of antiretroviral chemoprophylaxis on HIV-1 transmission in resource-limited settings. PLoS ONE, 2(9), e875.
2. Alliance for Microbicide Development (2006). Microbicide research and development database. (Accessed December 31, 2006); www.microbicide.org/cs/ microbiciderddatabase.
3. Auvert, B., Taljaard, D., Lagarde, E., Sobngwi-Tambekou, J., Sitta, R., & Puren, A. (2005). Randomized, controlled intervention trial of male circumcision for reduction of HIV infection risk: the ANRS 1265 Trial. PLoS Medicine, 2(11), e298.
4. Bailey, R. C., Moses, S., Parker, C. B., Agot, K., Maclean, I., Krieger, J. N., Williams, C. F., Campbell, R. T., & Ndinya-Achola, J. O. (2007). Male circumcision for HIV prevention in young men in Kisumu, Kenya: a randomised controlled trial. Lancet, 369(9562), 643-656.
5. Barnhart, K. T., Pretorius, E. S., Timbers, K., Shera, D., Shabbout, M., & Malamud, D. (2004). In vivo distribution of a vaginal gel: MRI evaluation of the effects of gel volume, time and simulated intercourse. Contraception, 70(6), 498-505.
6. Blower, S., Bodine, E., Kahn, J., & McFarland, W. (2005). The antiretroviral rollout and drug-resistant HIV in Africa: insights from empirical data and theoretical models. AIDS, 19(1), 1-14.
7. Coplan, P. M., Mitchnick, M., & Rosenberg, Z. F. (2004). Public health. Regulatory challenges in microbicide development. Science, 304(5679), 1911-1912.
8. Corey, L., Wald, A., Celum, C. L., & Quinn, T. C. (2004). The effects of Herpes Simplex Virus-2 on HIV-1 acquisition and transmission: a review of two overlapping epidemics. Journal of Acquired Immune Deficiency Syndromes, 35(5), 435-445.
9. Cunningham, C. K., Chaix, M. L., Rekacewicz, C., Britto, P., Rouzioux, C., Gelber, R. D., Dorenbaum, A., Delfraissy, J. F., Bazin, B., Mofenson, L., & Sullivan, J. L. (2002). Development of resistance mutations in women receiving standard antiretroviral therapy who received intrapartum nevirapine to prevent perinatal human immunodeficiency virus type 1 transmission: a substudy of pediatric AIDS clinical trials group protocol 316. The Journal of Infectious Diseases, 186(2), 181-188.
10. D'Cruz, O. J. & Uckun, F. M. (2004). Clinical development of microbicides for the prevention of HIV infection. Current Pharmaceutical Design, 10(3), 315-336.
11. Duerr, A., Wasserheit, J. N., & Corey, L. (2006). HIV vaccines: new frontiers in vaccine development. Clinical Infectious Diseases, 43(4), 500-511.
12. Eshleman, S. H. & Jackson, J. B. (2002). Nevirapine resistance after single dose prophylaxis. AIDS Reviews, 4(2), 59-63.
13. Fauci, A. S. (2006). Twenty-five years of HIV/AIDS. Science, 313(5786), 409.
14. Garg, S., Kandarapu, R., Vermani, K., Tambwekar, K. R., Garg, A., Waller, D. P., & Zaneveld, L. J. (2003). Development pharmaceutics of microbicide formulations. Part I: preformulation considerations and challenges. AIDS Patient Care and STDs, 17(1), 17-32.
15. Garg, S., Tambwekar, K. R., Vermani, K., Kandarapu, R., Garg, A., Waller, D. P., & Zaneveld, L. J. (2003). Development pharmaceutics of microbicide formulations. Part II: formulation, evaluation, and challenges. AIDS Patient Care and STDs, 17(8), 377-399.
16. Grant, R. M., Buchbinder, S., Cates, W., Jr., Clarke, E., Coates, T., Cohen, M. S., Delaney, M., Flores, G., Goicochea, P., Gonsalves, G., Harrington, M., Lama, J. R., MacQueen, K. M., Moore, J. P., Peterson, L., Sanchez, J., Thompson, M., & Wainberg, M. A. (2005). IDS. Promote HIV chemoprophylaxis research, don't prevent it. Science, 309(5744), 2170-2171.
17. Gray, R. H., Kigozi, G., Serwadda, D., Makumbi, F., Watya, S., Nalugoda, F., Kiwanuka, N., Moulton, L. H., Chaudhary, M. A., Chen, M. Z., Sewankambo, N. K., Wabwire-Mangen, F., Bacon, M. C., Williams, C. F., Opendi, P., Reynolds, S. J., Laeyendecker, O., Quinn, T. C., & Wawer, M. J. (2007). Male circumcision for HIV prevention in men in Rakai, Uganda: a randomised trial. Lancet, 369(9562), 657-666.
18. Haghighi, D. B. & Lashner, B. A. (2004). Left-sided ulcerative colitis. Gastroenterology Clinics of North America, 33(2), 271-84, ix.
19. Hillier, S. L., Moench, T., Shattock, R., Black, R., Reichelderfer, P., & Veronese, F. (2005). In vitro and in vivo: The Story of Nonoxynol 9. Journal of Acquired Immune Deficiency Syndromes, 39(1), 1-8.
20. Hu, J., Gardner, M. B., & Miller, C. J. (2000). Simian immunodeficiency virus rapidly penetrates the cervicovaginal mucosa after intravaginal inoculation and infects intraepithelial dendritic cells. Journal of Virology, 74(13), 6087-6095.
21. Kim, H. N., Tabet, S. R., Corey, L., & Celum, C. L. (2005). Antiretroviral therapy for HIV-1 vaccine efficacy trial participants who seroconvert. Vaccine, 24(3), 532-9.
22. Koblin, B., Chesney, M., Coates, T., & EXPLORE Study Team. (2004). Effects of a behavioural intervention to reduce acquisition of HIV infection among men who have sex with men: the EXPLORE randomised controlled study. Lancet, 364(9428), 41-50.
23. Lard-Whiteford, S. L., Matecka, D., O'Rear, J. J., Yuen, I. S., Litterst, C., Reichelderfer, P., & International Working Group on Microbicides. (2004). Recommendations for the nonclinical development of topical microbicides for prevention of HIV transmission: an update. Journal of Acquired Immune Deficiency Syndromes, 36(1), 541-552.
24. Mantell, J. E., Myer, L., Carballo-Dieguez, A., Stein, Z., Ramjee, G., Morar, N. S., & Harrison, P. F. (2005). Microbicide acceptability research: current approaches and future directions. Social Science & Medicine, 60(2), 319-330.
25. Mauck, C., Rosenberg, Z., & Van Damme, L. (2001). Recommendations for the clinical development of topical microbicides: an update. AIDS, 15(7), 857-868.
26. Mills, E., Rachlis, B., Wu, P., Wong, E., Wilson, K., & Singh, S. (2005). Media reporting of tenofovir trials in Cambodia and Cameroon. BMC International Health & Human Rights, 5, 6.
27. Neurath, A. R., Strick, N., & Li, Y. Y. (2003). Water dispersible microbicidal cellulose acetate phthalate film. BMC Infectious Diseases, 3, 27.
28. Owen, D. H., Peters, J. J., & Katz, D. F. (2000). Rheological properties of contraceptive gels. Contraception, 62(6), 321-326.
29. Padian, N. S., vander, Straten A., Ramjee, G., Chipato, T., de, Bruyn G., Blanchard, K., Shiboski, S., Montgomery, E. T., Fancher, H., Cheng, H., Rosenblum, M., vander, Laan M., Jewell, N., & McIntyre, J. (2007). Diaphragm and lubricant gel for prevention of HIV acquisition in southern African women: a randomised controlled trial. Lancet, 370(9583), 251-261.
30. Poles, M. A., Elliott, J., Taing, P., Anton, P. A., & Chen, I. S. (2001). A preponderance of CCR5 (+) CXCR4 (+) mononuclear cells enhances gastrointestinal mucosal susceptibility to human immunodeficiency virus type 1 infection. Journal of Virology, 75(18), 8390-8399.
31. Pretorius, A., Timbers, K., Malamud, D., & Barnhart, K. (2003). Magnetic resonance imaging to determine the distribution of a vaginal gel: before, during, and after both simulated and real intercourse. Contraception, 66(6), 443-451.
32. Ramjee, G., Govinden, R., Morar, N. S., & Mbewu, A. (2007). South Africa's experience of the closure of the cellulose sulphate microbicide trial. PLoS Medicine, 4(7), e235.
33. Sawires, S. R., Dworkin, S. L., Fiamma, A., Peacock, D., Szekeres, G., & Coates, T. J. (2007). Male circumcision and HIV/AIDS: challenges and opportunities. Lancet, 369(9562), 708-713.
34. Severy, L. J., Tolley, E., Woodsong, C., & Guest, G. (2005). A framework for examining the sustained acceptability of microbicides. AIDS and Behavior, 9(1), 121-131.
35. Sexton, A., Drake, P. M., Mahmood, N., Harman, S. J., Shattock, R. J., & Ma, J. K. (2006). Transgenic plant production of Cyanovirin-N, an HIV microbicide. FA S E B Journal, 20(2), 356-358.
36. Shattock, R. J. (2006). Protection of macaques against rectal SIV challenge by mucosally-applied PMPA. Presented at Microbicides 2006, Cape Town, South Africa (Abstract OA15).
37. Shattock, R. J. & Moore, J. P. (2003). Inhibiting sexual transmission of HIV-1 infection. Nature Reviews. Microbiology, 1(1), 25-34.
38. Stein, Z. A. (1990). HIV prevention: the need for methods women can use. American Journal of Public Health, 80(4), 460-462.
39. Tsai, C. C., Emau, P., Jiang, Y., Tian, B., Morton, W. R., Gustafson, K. R., & Boyd, M. R. (2003). Cyanovirin-N gel as a topical microbicide prevents rectal transmission of SHIV89.6P in macaques. AIDS Research and Human Retroviruses, 19(7), 535-541.
40. UNAIDS. (2006). 2006 Report on the global AIDS epidemic. Geneva. www.unaids.org:80/en/KnowledgeCentre/HIVData/GlobalReport/Default.asp.
41. US Food and Drug Administration. (2006). Additional resources regarding drug development of topical microbicides. (Accessed December 31, 2006); www.fda.gov/cder/ode4/preind/TopLinks.htm.
42. Van Damme, L., Ramjee, G., Alary, M., Vuylsteke, B., Chandeying, V., Rees, H., Sirivongrangson, P., Mukenge-Tshibaka, L., Ettiegne-Traore, V., Uaheowitchai, C., Karim, S. S., Masse, B., Perriens, J., & Laga, M. (2002). Effectiveness of COL-1492, a nonoxynol-9 vaginal gel, on HIV-1 transmission in female sex workers: a randomised controlled trial. Lancet, 360(9338), 971-977.
43. Veazey, R. S., Klasse, P. J., Schader, S. M., Hu, Q., Ketas, T. J., Lu, M., Marx, P. A., Dufour, J., Colonno, R. J., Shattock, R. J., Springer, M. S., & Moore, J. P. (2005). Protection of macaques from vaginal SHIV challenge by vaginally delivered inhibitors of virus-cell fusion. Nature, 438(7064), 99-102.
44. Woolfson, A. D., Malcolm, R. K., Morrow, R. J., Toner, C. F., & McCullagh, S. D. (2006). Intravaginal ring delivery of the reverse transcriptase inhibitor TMC 120 as an HIV microbicide. International Journal of Pharmaceutics, 325(1-2), 82-89.